INTRODUCTION: ASPIRIN-EXACERBATED RESPIRATORY DISEASE
Aspirin-exacerbated respiratory disease (AERD), known as NSAID-exacerbated respiratory disease (N-ERD) in Europe [1] , is a syndrome characterized by asthma, rhinitis, nasal polyps, excess mucus production, and eosinophilic inflammation, all worsened by the ingestion of medications that inhibit cyclooxygenase (COX)-1. The disease was first documented as a triad of symptoms (nasal polyps, nonallergic asthma, and aspirin sensitivity) by the French physician Ferdinand Widal in 1922 [2] . However, the condition first received widespread attention when it was described by Samter and Beers in 1968 [3] , and the three quintessential symptoms identified by Widal are now collectively referred to as 'Samter's triad' [4] . In addition to these symptoms, others may include sinus pain, cough, skin flushing, and/or urticarial rash in response to aspirin ingestion. Approximately 75% of patients with AERD also report respiratory reactions when consuming alcoholic beverages [5, 6] . The disease was identified in the context of aspirin sensitivity and named accordingly, but AERD confers intolerance to all COX-1, but not COX-2, inhibiting NSAIDs [7, 8] . AERD generally develops during the fourth decade of life [9, 10] . On average, the onset of AERD occurs 3 years earlier in women than in men, and women with AERD have 2.5 times the number of hospitalizations for asthma exacerbations compared to men with the condition. A recent meta-analysis of numerous AERD cohort studies estimates the prevalence of AERD to be 7% in the general population and 14% among individuals with severe asthma [11] . Compared to aspirin-tolerant asthmatic patients, individuals suffering from AERD are at a two-fold greater risk for having uncontrolled asthma, 80% more likely to visit the emergency room because of asthma attacks, and 60% more likely to be hospitalized for asthma [12] . Measuring a decrease in lung function after inhaled aspirin challenge remains the standard method of diagnosis for AERD. An increase in cysteinyl leukotrienes (CysLTs) in the urine after inhaled aspirin challenge is another indicator of AERD, and concentrations of LTE 4 , a CysLT, above 241 pg/mg Cr in the urine after aspirin challenge identifies a patient as positive for AERD with 92% specificity. However, most commercial laboratories are not equipped to quantify CysLTs, so the diagnostic utility of the urine test is limited [13] . Many patients do not notice that their asthmatic symptoms are connected to NSAID use, so physicians often do not consider administering aspirin challenge [14, 15] . As a result, AERD is underdiagnosed, and the true prevalence of the disease is likely higher. The central cause of AERD remained poorly understood until recently. In this review, we detail mechanisms underlying AERD pathogenesis. We outline the contributions of the CysLT pathway to AERD, and discuss how prostaglandin E 2 (PGE 2 ) signaling through the E prostanoid receptor 2 (EP 2 ) inhibits CysLT generation and restrains inflammation. We then discuss recent developments in our understanding of AERD and describe new pathways that contribute to this disease.
PATHOGENESIS OF ASPIRIN-EXACERBATED RESPIRATORY DISEASE: CYSTEINYL LEUKOTRIENES AND PROSTAGLANDIN E2
CysLTs are a principal driving force of AERD pathogenesis [16] . CysLTs, like prostaglandins, are downstream metabolic products of arachidonic acid. If 5-lipoxygenase catalyzes arachidonic acid, it becomes the CysLT precursor 5-hydroperoxyeicosatetraenoic acid, which can be metabolized to LTA 4 (Fig. 1) [17, 18] . LTA 4 may be metabolized to LTB 4 by the enzyme LTA 4 hydrolase [14, 18] . Alternatively, LTA 4 can be catalyzed by LTC 4 synthase to react with glutathione to produce LTC 4 and its downstream metabolites LTD 4 and LTE 4 . LTD 4 and LTE 4 act through multiple receptors and cell types to induce the canonical inflammatory phenotypes of asthma [18] . There are three CysLT receptors: CysLT 1 R, CysLT 2 R, and CysLT 3 R. CysLT 3 R was formerly known as GPR99 [19, 20] . LTC 4 and LTD 4 signal through CysLT 1 R to induce smooth-muscle contraction [21, 22] . Both human and guinea pig studies have implicated CysLT 2 R signaling in driving bronchoconstriction [23 & ,24,25] . LTE 4 signals through CysLT 1 R and CysLT 3 R, the latter of which stimulates mucin release and submucosal swelling in the nasal mucosa of mice [26] . Leukocyte-adhering platelets, mast cells, eosinophils, and basophils are the primary contributors to LTC 4 , LTD 4 , and LTE 4 production [27, 28] . CysLT 1 R is expressed on mast cells, macrophages, and granulocytes, leading to an enhanced, multicellular inflammatory reaction in response to LTC 4 , LTD 4 , and LTE 4 synthesis and signaling [29, 30 & ]. Increases in CysLTs further enhance Th2 inflammation by directly activating group 2 innate lymphoid cells (ILC2) through CysLT 1 R and by increasing the expression of other activating cytokine receptors such as thymic stromal lymphopoietin (TSLP) receptor and the IL-33 receptor subunit suppression of tumorigenicity 2 (ST2) [31, 32 && ]. These cells, their receptors, and their modes of activation will be discussed later.
One of the most important pieces of evidence that CysLTs are centrally involved in AERD is that LTE 4 levels increase directly in response to aspirin challenge in patients with AERD. The urine LTE 4 concentrations of patients intolerant to NSAIDs were nearly six-fold greater than those of their non-NSAID sensitive asthmatic counterparts [33] . Sinonasal tissue samples of patients with AERD had significantly increased levels of 5-lipoxygenase mRNA, LTC 4 , LTD 4 , and LTE 4 compared to healthy controls. 5-lipoxygenase mRNA, LTC 4 , LTD 4 , and LTE 4 all increased in proportion to the severity of AERD in the patients included in the test [34] . An increase in the expression of enzymes critical for leukotriene synthesis, as well as an increase in leukotriene receptors on inflammatory cells, partially explain disease pathogenesis in patients with AERD. Bronchial biopsies from NSAID-sensitive and nonsensitive patients revealed that those with AERD have a nearly 18-fold increase in the number of cells that express LTC 4 synthase, correlating with baseline CysLT levels [35, 36] . Nasal biopsy samples from AERD-
KEY POINTS
AERD is associated with increased CysLT production and expression of CysLT receptors. affected and nonaffected individuals revealed that patients with AERD had a nearly five-fold increase in the number of cells expressing CysLT 1 R in the airway, and the percentage of CD45 þ leukocytes expressing this receptor was similarly five-fold higher (25 vs. 5%) in patients with AERD [37] . In discussing the contributions of leukotrienes to AERD, these pathways require regulatory mechanisms to keep them from exhibiting severe pathological effects. PGE 2 signaling emerged as the primary candidate responsible for keeping the CysLT pathway in check, and deficiencies in PGE 2 synthesis and signaling are major contributors to AERD pathogenesis.
COX-1/COX-2 catalysis of arachidonic acid results in the generation of the unstable product prostaglandin H 2 (PGH 2 ). PGH 2 has five preliminary downstream conversion options depending on the tissue-specific synthases that may be expressed by a cell. PGH 2 can be converted to PGD 2 by lipocalintype PGD synthase or hematopoietic PGD synthase, PGI 2 by PGI synthase, thromboxane by thromboxane synthase, and PGF 2a by PGF synthase. Four [17, 38] . PGE 2 signals through four different receptors, E prostanoid receptor (EP 2 ) 1-4, with varying pro-inflammatory and anti-inflammatory functions, depending on the receptor through which PGE 2 signals [17] . In this regard, PGE 2 may have opposing functions within an individual cell depending on the level of expression of the individual EP receptors by that cell. PGE 2 attenuates the symptoms of asthma and promotes these protective effects by signaling through the EP 2 receptor [16] . PGE 2 plays a critical role in relaxing smooth muscle cells through EP 2 , allowing for a counteracting effect to leukotriene-mediated bronchoconstriction [39] . Many different leukocytes also express EP 2 , and PGE 2 /EP 2 regulates respiratory inflammation through a multitude of different pathways [40] . PGE 2 acts on CD4 þ T helper cells to decrease their expression of pro-inflammatory cytokines, such as TNF-a, and promotes alveolar macrophages to produce the anti-inflammatory cytokine IL-10 [41, 42] . PGE 2 also limits eosinophil migration through EP 2 signaling, attenuating the eosinophilia phenotype common in asthma and allergic disease [40, 43] . The PGE 2 /EP 2 axis downregulates degranulation of mast cells, leading to decreased histamine and tryptase levels [44, 45] . Finally, and most importantly, in regard to AERD, PGE 2 inhibits 5-lipoxygenase function, preventing the synthesis of leukotrienes [46] . This inhibition occurs by PGE 2 /EP 2 signaling increasing cAMP concentration within the target cell, preventing localization of 5-lipoxygenase to the nuclear envelope, which is necessary for LTA 4 synthesis [47] . There is evidence to suggest that the PGE 2 inhibition of 5-lipoxygenase activity might occur through an IL-10-dependent mechanism [48] .
As a result of PGE 2 's protective effects in the setting of asthma, reduction of PGE 2 synthesis via aspirin could contribute significantly to the pathophysiology characteristic of AERD. The prevailing explanation for the difference in effect of NSAIDs between individuals with and without AERD is that COX-2 is unable to synthesize an adequate quantity of PGH 2 (and eventually PGE 2 ) upon inhibition of COX-1 in patients with AERD [49] . Nasal polyp biopsies from patients with AERD suggest that COX-2 expression is insufficient to produce a level of PGE 2 that inhibits 5-lipoxygenase and generation of CysLTs [50] . The strongest evidence that PGE 2 signaling dysregulation drives AERD is that inhaled PGE 2 prevents respiratory reactions in patients with AERD who have been challenged with NSAIDs [51] . With PGE 2 inhalation, patients having AERD challenged with aspirin DL-lysine had no detectable increase in LTE 4 concentrations in the urine and no bronchoconstriction, indicated by no change in forced expiratory volume in 1 s. These results strongly suggest that PGE 2 has a protective role in AERD pathogenesis [51] .
It is important to consider the possibilities of decreased PGE 2 production, decreased EP 2 receptor expression, or a combination of both contributing to the dysregulation of the PGE 2 /EP 2 signaling axis in the pathogenesis of AERD. Recent evidence suggests that it is in fact a synergistic decrease in both PGE 2 levels and EP receptor density that contributes to the dysfunction of this protective pathway in AERD. There is a significant decrease in baseline PGE 2 levels in nasal tissue and peripheral blood cells in patients with AERD compared to healthy individuals, even without aspirin challenge [14, 16, 31, 34] . It is not merely a deficiency of PGE 2 itself that contributes to AERD, but an inability of PGE 2 to signal through EP 2 because of EP 2 's restricted expression. There is a significant decrease in EP 2 signaling in fibroblasts from nasal polyps of patients with AERD compared to healthy controls [52, 53] . Leukocytes in the nasal mucosa of patients with AERD expressed EP 2 to a significantly reduced degree compared to leukocytes of those without NSAID sensitivity [54] . A lower percentage of neutrophils, mast cells, macrophages, and T cells in the bronchial mucosa of patients with AERD expressed EP 2 compared to unaffected individuals [55] . These data strongly support that defective PGE 2 signaling is at the center of AERD pathogenesis.
RECENT ADVANCES: IL-33, THYMIC STROMAL LYMPHOPOIETIN, AND GROUP 2 INNATE LYMPHOID CELLS ARE INVOLVED IN ASPIRIN-EXACERBATED RESPIRATORY DISEASE, AND ARE REGULATED BY PROSTAGLANDIN E2
The relationship between CysLTs and PGE 2 has been investigated in the context of AERD for decades. However, more recent studies have described a role for IL-33 and TSLP in AERD, and their conclusions have offered a more complete picture regarding the involvement of leukotrienes and how their immunopathogenic effects can be amplified. IL-33 is a major cytokine involved in Th2-like immune responses, including allergic airway diseases. IL-33 is an alarmin cytokine of the IL-1 family predominantly expressed by tissue cell types, including epithelial cells, fibroblasts, and endothelial cells, whereas its expression may be induced in immune cells such as macrophages, mast cells, and dendritic cells. In epithelial cells, IL-33 is released in response to cell necrosis, physical stress, or activation by protease-containing aeroallergens [56] . In mice, IL-33 is predominantly expressed in the lung by alveolar type II pneumocytes, whereas in human lung, IL-33 is expressed by bronchial epithelial cells [56] . By binding to its receptor ST2, IL-33 stimulates receptorbearing cells to produce and secrete cytokines and growth factors that promote local and systemic immunity. ST2 is expressed on CD4 þ Th2 cells, mast cells, eosinophils, and ILC2. ILC2 are an innate lymphoid subset that are similar to CD4 þ Th2 lymphocytes, but they lack rearranged antigen-specific receptors so they are activated by soluble mediators such as IL-33, TSLP, and IL-25 [57, 58] . ILC2 secrete between seven and 10 times the quantity of IL-5, a cytokine critical for eosinophil recruitment and activation, compared with CD4 þ Th2 cells. ILC2 also release significant quantities of IL-13, which is a central mediator of airway responsiveness and mucous metaplasia [59] [60] [61] . In addition to IL-33, TSLP activates ILC2 and drives Th2 inflammation. TSLP signals through the TSLP receptor (TSLPR), which is expressed on a variety of cell types, including T lymphocytes, B lymphocytes, monocytes, CD11c þ dendritic cells, and mast cells [62] . TSLP acts synergistically with IL-33 in the production of IL-5 and IL-13 by ILC2 in the lung. The unique importance of TSLP in lung ILC2 has recently been defined. Although IL-33 activated ILC2 in the fat-associated lymphoid cluster of naïve mice, IL-33 alone was not able to induce IL-5 and IL-13 expression by mouse lung ILC2. Exogenous TSLP administration was required for the induction of large amounts of IL-5 and IL-13 from mouse lung ILC2 [59] . The CysLT and ILC2 pathways likely interact with one another to drive the symptoms of AERD, and enhanced activation of ILC2 occurs in individuals with AERD. The hypothesized interplay between the CysLT and ILC2 pathway that we describe is highlighted in the righthand side of Fig. 1 .
ILC2 express CysLT 1 R and CysLT 2 R, and signaling through these receptors leads to an enhancement of ILC2 responses in mouse models [31] . LTC 4 signaling through both CysLT 1 R and CysLT 2 R significantly increased the proliferation and pro-inflammatory cytokine expression of IL-33-activated ILC2 in mouse airways [ ]. To our knowledge, CysLT-dependent increases in IL-33 have only been investigated in type 2 pneumocytes. However, airway epithelial cells also express CysLT 2 R and CysLT 3 R [26, 66] . CysLT signaling through CysLT 3 R increased the expansion of brush cells secreting the pro-inflammatory cytokine IL-25, and CysLT 3 R signaling increased mucin release from respiratory epithelial cells [67 & ,68] . TSLP levels were significantly increased in the sputum of patients with AERD after aspirin desensitization [69 & ]. Six-month aspirin desensitization courses in patients with AERD led to increased levels of LTC 4 in the sputum at both the 1 and 6-month marks. Although aspirin desensitization decreased PGD 2 and increased PGE 2 , prolonged, elevated levels of CysLTs likely drove the increase of TSLP in the airway. These data suggest that there might be an increase in IL-33 and TSLP expression by epithelial cells in response to signaling through CysLT 2 R or CysLT 3 R, similar to type 2 pneumocytes. Further studies are necessary to identify the cell types in the respiratory tract that directly contribute to CysLT-induced increases in IL-33 and TSLP. In addition to CysLTs, IL-13 may increase the expression of IL-33. Administration of recombinant IL-13 to alveolar epithelial cells in vivo increased IL-33 expression more than eight-fold [70] .
IL-33 and TSLP that are expressed because of CysLT signaling are released into the airways in response to cell necrosis, physical stress, or activation by protease-containing aeroallergens [56] . As previously discussed, IL-33 and TSLP signaling drive ILC2 proliferation and IL-5/IL-13 production [57] . IL-33 and TSLP also activate mast cells. IL-33 induced the production and release of PGD 2 , TXB 2 , and LTC 4 by human mast cells in vitro [71] . IL-33 was necessary for aspirin-induced mast cell degranulation in a mouse model of AERD [72] . Exogenous LTE 4 induced mast cell degranulation, but LTE 4 in the setting of IL-33 neutralization by either antibodies or anti-ST2 Fc fusion protein caused no significant release of histamine or the pro-inflammatory mediator prostaglandin D 2 (PGD 2 ) from mast cells [72] . TSLP also directly stimulated human mast cells in vivo to produce PGD 2 . IL-33 acted synergistically with TSLP on mast cells in vivo to produce more PGD 2 compared to TSLP alone [73] . The interdependence of IL-33/TSLP, CysLT, and IL-13 pathway suggests a dangerous amplification mechanism that that can lead to enhanced inflammation and asthma in patients with AERD. The proposed mechanism is as follows. CysLT signaling is increased in patients with AERD, leading to an increase in IL-33 and TSLP. IL-33 and TSLP are released in episodes of inflammation, and they act synergistically with CysLTs to activate ILC2 and mast cells. ILC2 produce IL-5 and IL-13, and mast cells produce LTC 4 , histamine, TXB 2 , and PGD 2 . IL-13 induces increased expression of IL-33 in epithelial cells. Histamine, PGD 2 , and TXB 2 propagate the symptoms of asthma, and LTC 4 acts upstream to increase IL-33 and TSLP. IL-33 and TSLP continue to be expressed at high levels, and their release perpetuates a cyclic inflammatory response. This feed-forward mechanism has the potential for uncontrolled production of proinflammatory cytokines, leukotrienes, and histamine, leading to severe inflammation and bronchoconstriction.
We propose this synergistic pathway as an explanation for the severe respiratory symptoms that accompany AERD. There is substantial evidence to directly implicate IL-33 and TSLP in AERD pathogenesis. Nasal polyps isolated from patients diagnosed with AERD expressed significantly elevated levels of IL-33 compared to normal individuals. In a mouse model of AERD, deletion of the PGE synthase mPGES-1 increased baseline IL-33 in the lung, and concurrent deletion of LTC 4 synthase restored IL-33 to a normal level [72] . Concentrations of the cleaved, active form of TSLP were also significantly higher in the nasal polyps of patients with AERD compared to unaffected individuals [73] . ILC2 involvement in AERD is further evidenced by the recruitment of ILC2 to the nasal mucosa in patients with AERD upon NSAID challenge, whereas no change in tissue or blood ILC2 numbers occurred upon administration of NSAIDs to non-AERD individuals [74] . These recent data strongly suggest that IL-33 and TSLP accentuated the leukotriene-mediated inflammatory response by acting synergistically with CysLTs to activate mast cells and ILC2, contributing persistent Th2 inflammation to the AERD phenotype [75] .
We present evidence that implicates ILC2 as an important contributing cell type in AERD pathogenesis. Recent experiments with human tonsillar and blood ILC2 have shown that PGE 2 decreased ILC2 expression of its principal transcription factor GATA-3. PGE 2 also downregulated ILC2 production of IL-5 and IL-13, and PGE 2 decreased ILC2 proliferation in response to IL-33 and TSLP [76 && ]. PGE 2 's inhibitory effect on ILC2 is dependent on signaling through EP 2 and EP 4 , and PGE 2 signaling results in decreased expression of the IL-2 receptor a [77 & ]. Owing to the fact that PGE 2 exhibits protective effects against the symptoms of AERD, PGE 2 's ability to attenuate ILC2-mediated immunopathology further supports the involvement of the IL-33/TSLP-ILC2 axis in AERD.
CONCLUSION
In summary, investigations surrounding AERD and its pathogenesis implicate the dysregulation of the CysLT pathway as a primary contributor to disease pathogenesis. Increases in CysLTs and leukotriene receptors on a range of cell types in AERD enhance the pathogenic nature of the CysLT pathway. PGE 2 signaling through the EP 2 receptor is a potent negative regulator of the CysLT pathway. Decreased PGE 2 synthesis from reduced COX-2 expression is exacerbated by COX-1 inhibiting NSAIDs in individuals with AERD. Owing to the fact that all COX-1 inhibitors, but not all NSAIDs, cause adverse reactions in people with AERD, we propose the name COX-Oneinhibitor Exacerbated Respiratory Disease (COERD) as a more accurate alternative to AERD or N-ERD. Reduced PGE 2 synthesis in combination with decreased expression of EP 2 promotes CysLT synthesis and signaling in patients with AERD. Recent evidence suggests that IL-33 and TSLP play a central role in driving AERD pathogenesis. CysLTs increase IL-33 and TSLP in the respiratory tract, and IL-33/ TSLP act synergistically with CysLTs to activate ILC2 and mast cells. In AERD, ILC2 and mast cells produce mediators such as IL-13 to propagate Th2 inflammation and asthma, but mast cells also produce more LTC 4 . IL-13 and LTC 4 increase upstream IL-33/TSLP expression. This positive feedback mechanism is likely a main driving force in AERD. However, PGE 2 can inhibit ILC2 function, making it a viable therapeutic option for AERD and other ILC2-mediated diseases.
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